Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biostent catheter-delivered drug that blocks vascular remodeling: Began Phase I trial of four dose levels in 46 patients

NeoRx Corp. (NERX),

Read the full 34 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE